Home » Morphotek Presents Data From Ovarian Cancer Trial
Morphotek Presents Data From Ovarian Cancer Trial
Morphotek, Inc., a subsidiary of Eisai Corporation of North America, announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse.
News Blaze
News Blaze
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May